Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Laboratory Corporation of America Holdings has entered into an exclusive license agreement with Duke University Medical Center to commercialize Duke's new blood-based assay for early detection of lung cancer.
Subscribe to our email newsletter
The Duke technology is based on a collection of serum proteins associated with the biology of lung cancer.
Myla Lai-Goldman, executive vice president and medical director of LabCorp, said: “New diagnostic tools are required for lung cancer and this technology has the potential to stratify patients that may need more aggressive follow-up treatment and monitoring.”